What Panoramis Treats: Main Uses and Benefits

Panoramis is an endectocide formulation utilized to provide broad-spectrum protection by simultaneously addressing the three primary parasitic threats facing dogs. The core therapeutic function of the medication involves helping with managing fleas, preventing heartworm disease, and managing adult hookworm, roundworm, and whipworm infections.

The therapeutic benefit of this combination is applied in addressing conditions marked by both external irritation and common internal parasitic threats.

“This medication supports a comprehensive approach for continuous prophylactic defense against multiple serious parasitic infections.”

---

Protecting Against Life-Threatening Heartworm Disease

This medication provides essential prophylactic defense against the Asymptomatic Cardiopulmonary Threat. This protection contributes to the prevention of severe, systemic cardiopulmonary disease—a condition that progresses asymptomatically but can lead to severe damage. It assists with maintaining functional stability against this critical parasitic risk.

Quick Fact: Addresses Symptoms related to Physical Discomfort

Management of Flea Infestations and Gastrointestinal Worms

Panoramis is commonly applied to treat active flea infestations and sustain long-term prevention. Its action against the external parasite provides the key benefit of helping with easing intense skin irritation (pruritus). Furthermore, by addressing gastrointestinal nematode infections, it plays a role in managing the internal parasitic burden, which may assist with easing systemic issues such as the risk of anemia and chronic digestive upset.

---

Panoramis (also known as Trifexis) is a veterinary medicine for use only in dogs and puppies.

Populations for Use

Classification	Status & Requirements (Official Labeling)
Eligible Population	Dogs and puppies that are at least 8 weeks old and weigh 5 pounds (2.2 kg) or greater.
Contraindicated	Dogs with a known hypersensitivity to the active ingredients (spinosad or milbemycin oxime). The EMA label also contraindicates use in dogs under 14 weeks of age.
Restricted Use	Use in pregnant or lactating dogs is not sufficiently established and must be based on a veterinarian’s risk assessment. The safe use in breeding males has not been evaluated.
Caution Required	Use with caution in dogs with pre-existing epilepsy or a history of seizures. Prior to administration, dogs must be tested for heartworm infection and treated to remove adult heartworms if positive. Avermectin-sensitive dogs, such as certain Collie breeds, should be treated with special caution.

This medicine is restricted by Federal law (U.S.) to use by or on the order of a licensed veterinarian, who must determine the appropriateness of use based on the dog's age, weight, and clinical status.

The official regulatory documents define the interaction profile of Panoramis based on the activity of its components as substrates for the P-glycoprotein (P-gp) drug efflux transporter. This established pharmacokinetic interaction pattern necessitates specific warnings regarding co-administration.

Both active components, Spinosad and Milbemycin Oxime, are documented as P-gp substrates. Consequently, co-administration with other P-gp substrates, such as Digoxin or Doxorubicin, may lead to enhanced systemic exposure and potential enhanced toxicity of the co-administered agent. A population-dependent interaction consideration also exists: dogs with the MDR1 gene mutation are noted to be at a higher risk for adverse effects when P-gp interactions occur.

While no formally contraindicated combinations are documented in the regulatory prescribing information, a strong pharmacodynamic warning exists regarding extra-label use. Serious adverse reactions, including neurotoxic signs such as seizures and ataxia, have been reported following the extra-label co-administration of Spinosad (a component of Panoramis) with Ivermectin, which is another macrocyclic lactone.

Finally, the product itself exhibits an internal pharmacokinetic interaction: Spinosad causes a greater systemic exposure of Milbemycin Oxime than when Milbemycin Oxime is administered alone. This characteristic defines the systemic behavior of the fixed-dose combination. No timing-based interaction rules are specified in the official regulatory sections.

Dual-Mechanism Pharmacodynamics

Panoramis utilizes a dual-targeting strategy by engaging two fundamentally distinct molecular systems within the parasite's nervous system. The first component, Milbemycin Oxime, acts as an agonist at invertebrate-specific glutamate-gated chloride channels (GluCls). This interaction forces the channels open, causing a massive influx of Cl^- ions that hyperpolarizes nerve and muscle cells. This action functionally blocks signal transmission, resulting in flaccid paralysis of the target organism’s neuromuscular system.

The complementary mechanism involves Spinosad, which acts as an allosteric activator of nicotinic acetylcholine receptors (nAChRs) in the insect central nervous system. This persistent activation causes continuous motor neuron firing and sustained synaptic activity. The resulting hyperexcitation exhausts the organism's motor capacity, leading to spastic paralysis and neuromuscular failure.

This combined, non-overlapping interference ensures a comprehensive functional collapse of both inhibitory and excitatory pathways, resulting in systemic disruption.

The administration of Panoramis is defined by an official, standardized oral regimen that is consistently applied using a weight-based approach. The medication is supplied as a chewable tablet administered once monthly to meet a minimum dosage requirement of 30 mg/kg of Spinosad and 0.5 mg/kg of Milbemycin Oxime. The required tablet size is determined by matching the dog's weight to a specific tablet band, and dogs over 120 lbs necessitate an appropriate combination of tablets to ensure the correct dose is delivered.

To maximize the absorption of the active agents, the medication must be administered with food. The scheduling of this monthly dose can follow a continuous, year-round regimen, or a seasonal pattern. For seasonal use, treatment initiation must occur within one month of the initial expected exposure to parasitic organisms and must continue for at least three months following the last potential exposure.

The usage instructions also outline rules for specific populations, permitting use only in puppies aged eight weeks or older and weighing five pounds or greater. A procedural step requires that the dog is observed for one hour following administration. If vomiting occurs within this hour and the tablet is visible, the administration protocol requires that a full replacement dose be given to maintain the required systemic concentration. If a monthly dose is missed, it should be administered immediately with food, and the monthly schedule should then be resumed from that new date.

Research Evidence Overview of Studies for Panoramis

Evidence for Prophylactic Use Against Heartworm Disease

Research examining this combination was studied for the prevention of heartworm disease, and includes randomized, controlled laboratory challenge studies. These studies monitor and evaluate the assessment of non-establishment of adult heartworm following experimental exposure. Protocols utilized multiple consecutive monthly administrations when exploring outcomes related to certain heartworm isolates. Long-term data compiled from continuous, multi-year controlled trials is still being collected.

Evidence for Management of External Parasites (Fleas)

Research related to outcomes linked to inflammatory or irritative states from flea infestations was evaluated in multicentre field trials and controlled laboratory studies. Studies monitored outcomes related to physical discomfort, such as measured flea counts, and examined the speed of action (knockdown activity) and the residual effect over 30 days. Research is ongoing to monitor the emergence of patterns related to parasite resistance.

Evidence for Treatment of Gastrointestinal Nematode Infections

The research base was studied for internal parasites (hookworm, roundworm, and whipworm) includes randomized, controlled field trials and laboratory studies. Research examined patterns related to parasite counts and the monitoring of fecal egg counts following administration. These protocols primarily evaluated the outcomes of a single therapeutic administration, meaning limited information for long-term outcomes for continuous control remains.

Follow-up Duration and Research Gaps

The core research protocols involved observation periods of several months (e.g., four to six consecutive monthly administrations). Long-term effects are not fully established. Evidence was derived from studies of puppies starting at eight weeks of age; however, data for certain groups remain insufficient, including research exploring outcomes in pregnant or lactating dogs and in animals with comorbid conditions. Additionally, comparative evidence was not evaluated against all available treatment options, and certain findings were derived from experimental models.

Key Studies & References

1. Label: TRIFEXIS - spinosad and milbemycin oxime tablet - DailyMed - National Institutes of Health (NIH)
2. Assessment of the combination of spinosad and milbemycin oxime in preventing the development of canine Angiostrongylus vasorum infections (Lungworm Study)

Common questions about Panoramis (FAQ)

Q: Is Panoramis a flea and tick prevention or just one of them?

A: According to the official product label, Panoramis is approved for the prevention of heartworm disease and for the treatment and prevention of flea infestations. The regulatory documents for this product do not explicitly state an indication for the treatment or prevention of ticks.

Q: Is it normal for a dog to be a little sleepy after taking Panoramis?

A: Lethargy or depression is classified as a common adverse reaction in the official safety information for Panoramis. This may be observed as the dog being mildly sleepy after administration.

Q: Is Panoramis the same as Trifexis?

A: Yes, Panoramis and Trifexis refer to the same veterinary combination product. Panoramis is the trade name used in certain regions, while the product is known as Trifexis in others. Both contain the same two active ingredients: Spinosad and Milbemycin Oxime.

Q: Can Panoramis be given with other medications like allergy pills?

A: Caution is advised when Panoramis is given alongside other medications that use the P-glycoprotein (P-gp) transporter pathway, as this may increase the systemic exposure of the co-administered drug. Official warnings state that a veterinary professional should be informed of all co-administered medications to assess potential P-gp interactions.

Q: What happens if a dog misses a dose of Panoramis?

A: If a monthly dose is missed, regulatory instructions state that the dose should be administered immediately with food, and the regular monthly schedule should then be resumed from that new date. The product label states the proper procedure for a missed dose but does not provide clinical guidance on the period of compromised protection.

Q: Are there different sizes of Panoramis tablets for different weight dogs?

A: Yes, Panoramis is supplied in several strengths of chewable tablets. The tablet size required is determined by matching the dog's body weight to a specific weight band to ensure the correct minimum dosage of the active ingredients is delivered.

Q: Does Panoramis have a bitter taste that dogs usually reject?

A: The official product description notes that Panoramis is formulated as a highly palatable chewable tablet. This characteristic is intended to help ensure the dog accepts and consumes the oral dose successfully.

Q: Can dogs that have a sensitive stomach take Panoramis?

A: Common adverse reactions to Panoramis include vomiting and diarrhea, which affect the gastrointestinal system. A veterinary professional should be consulted regarding the dog's medical history and the potential for common gastrointestinal adverse reactions, as the product label does not provide specific cautions for pre-existing sensitive stomachs.

Q: Are there specific dog breeds that should not take Panoramis?

A: Official labeling advises that certain dog breeds, such as Collies, that are sensitive to Avermectins (a class of drugs related to one of the components) should be treated with special caution. This caution extends to dogs with the MDR1 gene mutation due to an increased risk of potential drug interactions.

Q: Can Panoramis be purchased online or only through a vet?

A: Panoramis is classified as a prescription veterinary medicine. In the U.S., Federal law restricts this medicine to use by or on the order of a licensed veterinarian.

Q: What should I do if my dog is already infested with fleas when I start Panoramis?

A: Panoramis is indicated for the treatment of flea infestations, as well as prevention. The official label instructions for administration are the same regardless of whether the dog is already infested or if treatment is being started for prevention.

Q: Does Panoramis protect against intestinal worms?

A: Panoramis is officially indicated for the treatment and control of infections caused by specific gastrointestinal parasites, specifically hookworm, roundworm, and whipworm. The official indication is for the treatment and control of these infections, and not as a broad, long-term preventative against all worms.

Q: Can a dog that has seizures take Panoramis?

A: Official safety information requires that Panoramis be used with caution in dogs with pre-existing epilepsy or a history of seizures. Furthermore, seizures are documented as an uncommon adverse reaction in the general dog population.

Q: What if my dog is pregnant and accidentally takes Panoramis?

A: The safe use of Panoramis in breeding, pregnant, or lactating dogs has not been fully established through sufficient studies. If the product is administered to a pregnant animal, official safety information indicates that use in this population requires a veterinary professional's assessment of the risks and benefits.

Q: Does Panoramis need to be stored in the refrigerator?

A: No, Panoramis does not require refrigeration. Official instructions state the product must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), to maintain its integrity.

Q: If Panoramis contains an insecticide, is it safe for dogs?

A: The product has been approved by regulatory bodies, such as the FDA, as safe and effective for dogs when administered in accordance with the official label. The regulatory approval for this veterinarian medicine is based on submitted safety and efficacy data.

How to Store and Dispose of Panoramis

Official regulatory labeling dictates strict conditions for the storage and disposal of Panoramis (Spinosad/Milbemycin Oxime) to maintain product integrity and safety.

---

Storage Requirements

Storage Component	Official Requirement
Temperature	Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Protection	Keep in the original foil packet to protect from light, moisture, and excessive heat.
Safety	The product must be stored out of the sight and reach of children and pets.
Stability	Do not use the chewable tablets past the expiration date (EXP) printed on the packaging.

---

Disposal Instructions

Any unused or expired veterinary medicinal product and associated waste materials must be disposed of according to local regulatory requirements. The official instructions advise against release into the environment, emphasizing compliance with local procedures for medicinal waste disposal.